But Pfizer and Bristol-Myers Squibb, one with a new boss and the other still looking, had better be taking notes.

FORBES: Taking Their Medicine

Merck, Eli Lilly, Pfizer and Bristol-Myers Squibb now are yield stocks with just some promise of financial engineering like stock buybacks and dispositions of stagnant divisions.

FORBES: Open Season On Icons, From Apple And Google To Charlie Sheen

Pfizer and partner Bristol-Myers Squibb Co. will promote it jointly, noting its advantages over two rival drugs on the market already, Xarelto and Pradaxa.

WSJ: Pfizer Q4 net jumps on sale of nutrition business